VRCA
NASDAQ · Pharmaceuticals
Verrica Pharmaceuticals Inc
$6.27
-0.10 (-1.57%)
Financial Highlights (FY 2026)
Revenue
74.80M
Net Income
-37,605,252
Gross Margin
90.3%
Profit Margin
-50.3%
Rev Growth
+57.9%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 90.3% | 90.3% | 66.6% | 66.6% |
| Operating Margin | -38.6% | -34.7% | 28.7% | 26.8% |
| Profit Margin | -50.3% | -47.8% | 18.9% | 25.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 74.80M | 47.36M | 35.73M | 38.70M |
| Gross Profit | 67.57M | 42.78M | 23.80M | 25.78M |
| Operating Income | -28,842,269 | -16,435,381 | 10.25M | 10.38M |
| Net Income | -37,605,252 | -21,428,850 | 6.74M | 10.01M |
| Gross Margin | 90.3% | 90.3% | 66.6% | 66.6% |
| Operating Margin | -38.6% | -34.7% | 28.7% | 26.8% |
| Profit Margin | -50.3% | -47.8% | 18.9% | 25.9% |
| Rev Growth | +57.9% | +57.9% | +7.9% | +5.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.86M | 2.86M | 41.09M | 34.59M |
| Total Equity | 67.36M | 67.36M | 73.14M | 69.93M |
| D/E Ratio | 0.04 | 0.04 | 0.56 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -27,827,125 | -16,737,855 | 12.85M | 15.80M |
| Free Cash Flow | — | — | 8.80M | 7.67M |